Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
Leading theories on the pathophysiology of Alzheimer disease (AD) implicate overproduction of amyloid-β (Aβ), particularly 42 amino acid peptide Aβ42.1-3 Compounds modulating γ-secretase enzyme cleaving β-amyloid precursor protein (APP) to release various forms of Aβ are candidates for treatment of AD. One such compound is tarenflurbil (formerly R-flurbiprofen), a selective Aβ42-lowering agent that has been shown in vitro and in vivo to modulate γ-secretase activity and reduce Aβ42 production in favor of shorter less toxic forms of Aβ (eg, Aβ38 and Aβ37).4,5 In mouse models of AD, tarenflurbil prevents learning and memory deficits and reduces Aβ42 brain concentrations.4,6